Research and Markets (http://www.researchandmarkets.com/research/zbkcd9/acute_lung_injury) has announced the addition of the "Acute Lung Injury - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Acute Lung Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
It also reviews key players involved in the therapeutic development for Acute Lung Injury and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Mentioned:
- Altor BioScience Corporation
- Apeptico Forschung und Entwicklung GmbH
- Bayer AG
- BioMarck Pharmaceuticals, Ltd.
- Carolus Therapeutics, Inc.
- CompleGen, Inc.
- FirstString Research, Inc.
- GlaxoSmithKline Plc
- Histocell S.L.
- Navigen Pharmaceuticals, Inc.
- Noxxon Pharma AG
- Quark Pharmaceuticals, Inc.
- S-Evans Biosciences, Inc.
- Silence Therapeutics Plc
- Stemedica Cell Technologies, Inc.
- Xiber Science GmbH
Key Topics Covered:
- Introduction
- Acute Lung Injury Overview
- Therapeutics Development
- Pipeline Products for Acute Lung Injury - Overview
- Pipeline Products for Acute Lung Injury - Comparative Analysis
- Acute Lung Injury - Therapeutics under Development by Companies
- Acute Lung Injury - Therapeutics under Investigation by Universities/Institutes
- Acute Lung Injury - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Acute Lung Injury - Products under Development by Companies
- Acute Lung Injury - Products under Investigation by Universities/Institutes
-
Acute Lung Injury - Companies Involved in Therapeutics Development
For more information visit http://www.researchandmarkets.com/research/zbkcd9/acute_lung_injury
View source version on businesswire.com: http://www.businesswire.com/news/home/20160129005423/en/
